How Much Potential Do Nucleoside Analogs Offer to Combat Human Corona Viruses?

References (129)

1. 1 Weiss, 2020, Forty Years with Coronaviruses [DOI]
2. 2 Guarner, 2020, Three Emerging Coronaviruses in Two Decades [DOI]
3. 3 WHO Regional Office for the Western Pacific (2006). SARS: How a Global Epidemic Was Stopped, WHO Regional Office for the Western Pacific.
4. 4 Azhar, 2019, The Middle East Respiratory Syndrome (MERS) [DOI]
5. 5 (2023, June 05). Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Available online: https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers.
6. 6 (2023, June 05). Weekly Epidemiological Update on COVID-19—1 June 2023. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-june-2023.
7. 7 (2023, June 05). WHO Chief Declares End to COVID-19 as a Global Health Emergency|UN News. Available online: https://news.un.org/en/story/2023/05/1136367.
8. 8 Marra, 2003, The Genome Sequence of the SARS-Associated Coronavirus [DOI]
9. 9 Kandeil, 2016, Complete Genome Sequence of Middle East Respiratory Syndrome Coronavirus Isolated from a Dromedary Camel in Egypt [DOI]
10. 10 Naqvi, A.A.T., Fatima, K., Mohammad, T., Fatima, U., Singh, I.K., Singh, A., Atif, S.M., Hariprasad, G., Hasan, G.M., and Hassan, M.d.I. (2020). Insights into SARS-CoV-2 Genome, Structure, Evolution, Pathogenesis and Therapies: Structural Genomics Approach. Biochim. Biophys. Acta BBA Mol. Basis Dis., 1866. [DOI]
11. 11 Morse, 2020, Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV [DOI]
12. 12 Li, 2020, Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV) [DOI]
13. 13 Martinez, 2020, Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus [DOI]
14. 14 Gillner, 2019, Selected Nucleos(t)Ide-Based Prescribed Drugs and Their Multi-Target Activity [DOI]
15. 15 Koren, 2003, Ribavirin in the Treatment of SARS: A New Trick for an Old Drug?
16. 16 Barnard, 2006, Enhancement of the Infectivity of SARS-CoV in BALB/c Mice by IMP Dehydrogenase Inhibitors, Including Ribavirin [DOI]
17. 17 Li, 2023, Therapeutic Strategies for COVID-19: Progress and Lessons Learned [DOI]
18. 18 Horga, 2023, Phase II Study of Bemnifosbuvir in High-Risk Participants in a Hospital Setting with Moderate COVID-19 [DOI]
19. 19 Jordan, 2018, Nucleosides for the Treatment of Respiratory RNA Virus Infections [DOI]
20. 20 Pruijssers, 2019, Nucleoside Analogues for the Treatment of Coronavirus Infections [DOI]
21. 21 Totura, 2019, Broad-Spectrum Coronavirus Antiviral Drug Discovery [DOI]
22. 22 Yan, 2020, Research Progress of Drug Treatment in Novel Coronavirus Pneumonia [DOI]
23. 23 Ami, 2021, Intriguing Antiviral Modified Nucleosides: A Retrospective View into the Future Treatment of COVID-19 [DOI]
24. 24 Roy, 2022, Nucleosides and Emerging Viruses: A New Story [DOI]
25. 25 Borbone, N., Piccialli, G., Roviello, G.N., and Oliviero, G. (2021). Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses. Molecules, 26. [DOI]
26. 26 Thames, 2022, Comparison of the Old and New—Novel Mechanisms of Action for Anti-Coronavirus Nucleoside Analogues [DOI]
27. 27 Xu, X., Chen, Y., Lu, X., Zhang, W., Fang, W., Yuan, L., and Wang, X. (2022). An Update on Inhibitors Targeting RNA-Dependent RNA Polymerase for COVID-19 Treatment: Promises and Challenges. Biochem. Pharmacol., 205. [DOI]
28. 28 Bekheit, 2023, Potential RNA-Dependent RNA Polymerase (RdRp) Inhibitors as Prospective Drug Candidates for SARS-CoV-2 [DOI]
29. 29 Zenchenko, 2021, Nucleoside Inhibitors of Coronaviruses [DOI]
30. 30 Cinatl, 2003, Glycyrrhizin, an Active Component of Liquorice Roots, and Replication of SARS-Associated Coronavirus [DOI]
31. 31 Barnard, 2004, Inhibition of Severe Acute Respiratory Syndrome-Associated Coronavirus (SARSCoV) by Calpain Inhibitors and Beta-D-N4-Hydroxycytidine [DOI]
32. 32 Barnard, 2006, Evaluation of Immunomodulators, Interferons and Known in Vitro SARS-CoV Inhibitors for Inhibition of SARS-Cov Replication in BALB/c Mice [DOI]
33. 33 Asper, 2004, Application of Real-Time PCR for Testing Antiviral Compounds against Lassa Virus, SARS Coronavirus and Ebola Virus in Vitro [DOI]
34. 34 Chen, 2004, In Vitro Susceptibility of 10 Clinical Isolates of SARS Coronavirus to Selected Antiviral Compounds [DOI]
35. 35 Saijo, 2005, Inhibitory Effect of Mizoribine and Ribavirin on the Replication of Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus [DOI]
36. 36 Sheahan, 2020, An Orally Bioavailable Broad-Spectrum Antiviral Inhibits SARS-CoV-2 in Human Airway Epithelial Cell Cultures and Multiple Coronaviruses in Mice [DOI]
37. 37 Ikejiri, 2007, Synthesis and Biological Evaluation of Nucleoside Analogues Having 6-Chloropurine as Anti-SARS-CoV Agents [DOI]
38. 38 Chu, 2006, Antiviral Activity of Nucleoside Analogues against SARS-Coronavirus (SARS-CoV) [DOI]
39. 39 Dyall, 2014, Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection [DOI]
40. 40 Warren, 2014, Protection against Filovirus Diseases by a Novel Broad-Spectrum Nucleoside Analogue BCX4430 [DOI]
41. 41 Peters, 2015, Design, Synthesis and Evaluation of a Series of Acyclic Fleximer Nucleoside Analogues with Anti-Coronavirus Activity [DOI]
42. 42 Sheahan, 2017, Broad-Spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses [DOI]
43. 43 Agostini, 2018, Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease [DOI]
44. 44 Good, 2021, AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19 [DOI]
45. 45 Cho, 2006, Synthesis of Cyclopentenyl Carbocyclic Nucleosides as Potential Antiviral Agents Against Orthopoxviruses and SARS [DOI]
46. 46 Cho, 2012, Synthesis and Antiviral Activity of a Series of 1′-Substituted 4-Aza-7,9-Dideazaadenosine C-Nucleosides [DOI]
47. 47 Yoon, 2019, Design, Synthesis, and Anti-RNA Virus Activity of 6′-Fluorinated-Aristeromycin Analogues [DOI]
48. 48 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT03891420. A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19, Available online: https://classic.clinicaltrials.gov/ct2/show/NCT03891420?term=NCT03891420&draw=2&rank=1.
49. 49 BioCryst (2023, June 19). Provides Update on Galidesivir Program|BioCryst Pharmaceuticals. Available online: https://ir.biocryst.com/news-releases/news-release-details/biocryst-provides-update-galidesivir-program.
50. 50 Taylor, R., Bowen, R., Demarest, J.F., DeSpirito, M., Hartwig, A., Bielefeldt-Ohmann, H., Walling, D.M., Mathis, A., and Babu, Y.S. (2021). Activity of Galidesivir in a Hamster Model of SARS-CoV-2. Viruses, 14. [DOI]
51. 51 Ogando, N.S., Zevenhoven-Dobbe, J.C., Jarhad, D.B., Tripathi, S.K., Lee, H.W., Jeong, L.S., Snijder, E.J., and Posthuma, C.C. (2021). 6′,6′-Difluoro-Aristeromycin Is a Potent Inhibitor of MERS-Coronavirus Replication. bioRxiv. [DOI]
52. 52 Zandi, 2020, Repurposing Nucleoside Analogs for Human Coronaviruses [DOI]
53. 53 Xie, 2021, Design and Development of an Oral Remdesivir Derivative VV116 against SARS-CoV-2 [DOI]
54. 54 Schultz, 2022, Pyrimidine Inhibitors Synergize with Nucleoside Analogues to Block SARS-CoV-2 [DOI]
55. 55 Wang, 2020, Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro [DOI]
56. 56 Uemura, 2021, 5-Hydroxymethyltubercidin Exhibits Potent Antiviral Activity against Flaviviruses and Coronaviruses, Including SARS-CoV-2 [DOI]
57. 57 Sacramento, 2021, In Vitro Antiviral Activity of the Anti-HCV Drugs Daclatasvir and Sofosbuvir against SARS-CoV-2, the Aetiological Agent of COVID-19 [DOI]
58. 58 Ellinger, 2021, A SARS-CoV-2 Cytopathicity Dataset Generated by High-Content Screening of a Large Drug Repurposing Collection [DOI]
59. 59 Bergant, 2022, Attenuation of SARS-CoV-2 Replication and Associated Inflammation by Concomitant Targeting of Viral and Host Cap 2′-O-Ribose Methyltransferases [DOI]
60. 60 Bennett, 2022, Sangivamycin Is Highly Effective against SARS-CoV-2 in Vitro and Has Favorable Drug Properties [DOI]
61. 61 Rabie, 2022, Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication [DOI]
62. 62 Rabie, 2022, Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease [DOI]
63. 63 Rabie, 2022, A Series of Adenosine Analogs as the First Efficacious Anti-SARS-CoV-2 Drugs against the B.1.1.529.4 Lineage: A Preclinical Repurposing Research Study [DOI]
64. 64 Abdalla, M., and Rabie, A.M. (2023). Dual Computational and Biological Assessment of Some Promising Nucleoside Analogs against the COVID-19-Omicron Variant. Comput. Biol. Chem., 104. [DOI]
65. 65 Rabie, 2022, Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV-2 Repurposing Potential: In Silico and In Vitro Studies [DOI]
66. 66 Rabie, 2023, Evaluation of a Series of Nucleoside Analogs as Effective Anticoronaviral-2 Drugs against the Omicron-B.1.1.529/BA.2 Subvariant: A Repurposing Research Study [DOI]
67. 67 Lin, 2022, Azacytidine Targeting SARS-CoV-2 Viral RNA as a Potential Treatment for COVID-19 [DOI]
68. 68 Yu, 2020, Azvudine (FNC): A Promising Clinical Candidate for COVID-19 Treatment [DOI]
69. 69 Zhang, 2021, Azvudine Is a Thymus-Homing Anti-SARS-CoV-2 Drug Effective in Treating COVID-19 Patients [DOI]
70. 70 Yu, 2022, The First Chinese Oral Anti-COVID-19 Drug Azvudine Launched
71. 71 Milisavljevic, 2021, Antiviral Activity of 7-Substituted 7-Deazapurine Ribonucleosides, Monophosphate Prodrugs, and Triphoshates against Emerging RNA Viruses [DOI]
72. 72 Schooley, 2021, Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs [DOI]
73. 73 Lo, 2021, Broad-Spectrum In Vitro Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524) [DOI]
74. 74 Cao, 2022, The Adenosine Analog Prodrug ATV006 Is Orally Bioavailable and Has Preclinical Efficacy against Parental SARS-CoV-2 and Variants [DOI]
75. 75 Wen, Z.-H., Wang, M.-M., Li, L.-Y., Herdewijn, P., Snoeck, R., Andrei, G., Liu, Z.-P., and Liu, C. (2023). Synthesis and Anti-SARS-CoV-2 Evaluation of Lipid Prodrugs of β-D-N4-Hydroxycytidine (NHC) and a 3′-Fluoro-Substituted Analogue of NHC. Bioorganic Chem., 135. [DOI]
76. 76 Bege, M., Kiss, A., Bereczki, I., Hodek, J., Polyák, L., Szemán-Nagy, G., Naesens, L., Weber, J., and Borbás, A. (2022). Synthesis and Anticancer and Antiviral Activities of C-2′-Branched Arabinonucleosides. Int. J. Mol. Sci., 23. [DOI]
77. 77 (2023, September 24). Tonix Seeks to Advance OyaGen’s COVID-19 Treatment Under New Global Licensing Deal. Available online: https://www.biospace.com/article/tonix-seeks-to-advance-oyagen-s-covid-19-treatment-under-new-global-licensing-deal/.
78. 78 Bibi, 2022, Cordycepin as a Promising Inhibitor of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp) [DOI]
79. 79 Ye, Y. (2022). Nature, Springer Nature Limited.
80. 80 McCarthy, 2023, VV116 as a Potential Treatment for COVID-19 [DOI]
81. 81 Chan, 2013, Broad-Spectrum Antivirals for the Emerging Middle East Respiratory Syndrome Coronavirus [DOI]
82. 82 Warren, 2016, Therapeutic Efficacy of the Small Molecule GS-5734 against Ebola Virus in Rhesus Monkeys [DOI]
83. 83 Agostini, 2019, Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance [DOI]
84. 84 Parang, K., El-Sayed, N.S., Kazeminy, A.J., and Tiwari, R.K. (2020). Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs against Human Coronavirus 229E (HCoV-229E). Molecules, 25. [DOI]
85. 85 Andrei, 2017, Design, Synthesis, and the Biological Evaluation of a New Series of Acyclic 1,2,3-Triazole Nucleosides [DOI]
86. 86 Pyrc, 2006, van der Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle [DOI]
87. 87 Bouvet, M., Debarnot, C., Imbert, I., Selisko, B., Snijder, E.J., Canard, B., and Decroly, E. (2010). In Vitro Reconstitution of SARS-Coronavirus mRNA Cap Methylation. PLoS Pathog., 6, Correction in PLoS Pathog. 2010, 6. [DOI]
88. 88 Aouadi, 2016, Binding of the Methyl Donor S-Adenosyl-l-Methionine to Middle East Respiratory Syndrome Coronavirus 2′-O-Methyltransferase Nsp16 Promotes Recruitment of the Allosteric Activator Nsp10 [DOI]
89. 89 Gordon, 2020, Remdesivir Is a Direct-Acting Antiviral That Inhibits RNA-Dependent RNA Polymerase from Severe Acute Respiratory Syndrome Coronavirus 2 with High Potency [DOI]
90. 90 Ju, 2020, Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase [DOI]
91. 91 Chien, 2020, Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19 [DOI]
92. 92 Jockusch, 2020, Sofosbuvir Terminated RNA Is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir [DOI]
93. 93 Lu, 2020, Development of a Simple In Vitro Assay To Identify and Evaluate Nucleotide Analogs against SARS-CoV-2 RNA-Dependent RNA Polymerase [DOI]
94. 94 Devkota, 2021, Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors [DOI]
95. 95 Klima, 2022, Crystal Structure of SARS-CoV-2 Nsp10–Nsp16 in Complex with Small Molecule Inhibitors, SS148 and WZ16 [DOI]
96. 96 Li, F., Ghiabi, P., Hajian, T., Klima, M., Li, A.S.M., Khalili Yazdi, A., Chau, I., Loppnau, P., Kutera, M., and Seitova, A. (2023). SS148 and WZ16 Inhibit the Activities of Nsp10-Nsp16 Complexes from All Seven Human Pathogenic Coronaviruses. Biochim. Biophys. Acta Gen. Subj., 1867. [DOI]
97. 97 Kuzikov, 2021, Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen [DOI]
98. 98 Sourimant, 2022, 4′-Fluorouridine Is an Oral Antiviral That Blocks Respiratory Syncytial Virus and SARS-CoV-2 Replication [DOI]
99. 99 Zhao, 2022, 5-Iodotubercidin Inhibits SARS-CoV-2 RNA Synthesis [DOI]
100. 100 Schindewolf, 2023, SARS-CoV-2 Uses Nonstructural Protein 16 To Evade Restriction by IFIT1 and IFIT3 [DOI]
101. 101 Guiraud, 2020, Synthesis of Adenine Dinucleosides SAM Analogs as Specific Inhibitors of SARS-CoV Nsp14 RNA Cap Guanine-N7-Methyltransferase [DOI]
102. 102 Otava, 2021, The Structure-Based Design of SARS-CoV-2 Nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors [DOI]
103. 103 Bobrovs, 2021, Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate [DOI]
104. 104 Bobileva, O., Bobrovs, R., Sirma, E.E., Kanepe, I., Bula, A.L., Patetko, L., Ramata-Stunda, A., Grinberga, S., Jirgensons, A., and Jaudzems, K. (2023). 3-(Adenosylthio)Benzoic Acid Derivatives as SARS-CoV-2 Nsp14 Methyltransferase Inhibitors. Molecules, 28. [DOI]
105. 105 Hausdorff, 2022, Potent Inhibition of SARS-CoV-2 Nsp14 N7-Methyltransferase by Sulfonamide-Based Bisubstrate Analogues [DOI]
106. 106 Amador, 2022, Facile Access to 4′-(N-Acylsulfonamide) Modified Nucleosides and Evaluation of Their Inhibitory Activity against SARS-CoV-2 RNA Cap N7-Guanine-Methyltransferase Nsp14 [DOI]
107. 107 Jung, 2022, Bisubstrate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase [DOI]
108. 108 Hausdorff, 2023, Structure-Guided Optimization of Adenosine Mimetics as Selective and Potent Inhibitors of Coronavirus Nsp14 N7-Methyltransferases [DOI]
109. 109 Elis, 1972, New Indications for 6-Azauridine Treatment in Man. A Review [DOI]
110. 110 Sun, 2015, Preclinical Pharmacokinetic Studies of 3-Deazaneplanocin A, a Potent Epigenetic Anticancer Agent, and Its Human Pharmacokinetic Prediction Using GastroPlusTM [DOI]
111. 111 Bisel, 1970, Clinical Studies with Tubercidin Administered by Direct Intravenous Injection
112. 112 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04280705. Adaptive COVID-19 Treatment Trial (ACTT), Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04280705?term=NCT04280705&draw=2&rank=1.
113. 113 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04292730. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment, Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04292730?term=NCT04292730&draw=2&rank=1.
114. 114 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04292899. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe Coronavirus Disease (COVID-19), Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04292899?term=NCT04292899&draw=2&rank=1.
115. 115 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04401579. Adaptive COVID-19 Treatment Trial 2 (ACTT-2), Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04401579?term=NCT04401579&draw=2&rank=1.
116. 116 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04409262. A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared with Remdesivir Plus Placebo in Hospitalized Participants with Severe COVID-19 Pneumonia (REMDACTA), Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04409262?term=NCT04409262&draw=2&rank=1.
117. 117 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04492475. Adaptive COVID-19 Treatment Trial 3 (ACTT-3), Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04492475?term=NCT04492475&draw=2&rank=1.
118. 118 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04539262. Study in Participants with Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation, Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04539262?term=NCT04539262&draw=2&rank=1.
119. 119 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04546581. Inpatient Treatment of COVID-19 with Anti-Coronavirus Immunoglobulin (ITAC), Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04546581?term=NCT04546581&draw=2&rank=1.
120. 120 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04583956. ACTIV-5/Big Effect Trial (BET-A) for the Treatment of COVID-19, Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04583956?term=NCT04583956&draw=2&rank=1.
121. 121 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Med-icine. Identifier NCT04593940. Immune Modulators for Treating COVID-19 (ACTIV-1 IM), Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04593940?term=NCT04593940&draw=2&rank=1.
122. 122 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04988035. ACTIV-5/Big Effect Trial (BET-C) for the Treatment of COVID-19, Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04988035?term=NCT04988035&draw=2&rank=1.
123. 123 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04405570. Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons with COVID-19, Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04405570?term=NCT04405570&draw=2&rank=1.
124. 124 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04392219. COVID-19 First in Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers, Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04392219?term=NCT04392219&draw=2&rank=1.
125. 125 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04405739. The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID), Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04405739?term=NCT04405739&draw=2&rank=1.
126. 126 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04575597. Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants with COVID-19 (MK-4482-002), Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04575597?term=NCT04575597&draw=2&rank=1.
127. 127 (2024, April 22). ClinicalTrials.gov [Internet]. U.S. National Library of Medicine. Identifier NCT04709835. Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients with Mild or Moderate COVID-19, Available online: https://classic.clinicaltrials.gov/ct2/show/NCT04709835?term=NCT04709835&draw=2&rank=1.
128. 128 Kim, S.E. (2023, September 19). Long COVID: The Hunt for Causes and Cures. Available online: https://cen.acs.org/biological-chemistry/infectious-disease/Long-COVID-hunt-causes-cures/101/i30.
129. 129 (2023, September 18). Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study. Available online: https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating.

Cited by 2

Related research

• Epstein-Barr Virus; A Nascent Viral Link with Oral Squamous Cell Carcinoma — shares topic coverage
• Image-Based Identification of Cell Cultures by Machine Learning — shares topic coverage
• Phytobiomes: Harnessing the Power of Microbial Communities for Plant Health — shares topic coverage
• Thermostability and in-vitro Antibacterial Activity of Aqueous Extracts of Tetrapleura tetraptera Pods on Multidrug Resistant Clinical Isolates — shares topic coverage
• Acute Toxicity, Phytochemistry and Anti-diarrheal Effects of Celtis integrifolia Lam. Aqueous Leaf Extract in Wistar Albino Rats — shares topic coverage